Finland· FI-REL-REL59029
Opdualag
A nivolumab and relatlimab product containing nivolumab + relatlimab, registered in Finland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Nivolumab and relatlimab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FY02 (nivolumab and relatlimab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Nivolumab and relatlimab · ATC L01FY02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Nivolumab + Relatlimab
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Finland (FI)
- ATC code
- L01FY02
- ATC class
- Nivolumab and relatlimab
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nivolumab and relatlimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaOPDUALAGBRISTOL-MYERS SQUIBB CANADA
- SwitzerlandOpdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml), Konzentrat zur Herstellung einer InfusionslösungBristol-Myers Squibb SA
- CzechiaOPDUALAGBristol-Myers Squibb Pharma EEIG, Dublin
- SpainOPDUALAG 240 MG/80 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FranceOPDUALAG 240 mg/80 mg, solution à diluer pour perfusionBRISTOL-MYERS SQUIBB / PFIZER EEIG (IRLANDE)
- United KingdomOpdualag 240mg/20ml / 80mg/20ml concentrate for solution for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandOpdualag 240 mg/80 mg sterile concentrateBristol-Myers Squibb Pharma EEIG
- IcelandOpdualagBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Opdualag
- Liechtenstein · Opdualag
- Norway · Opdualag
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9cb48086-6883-4358-bd31-b986f04d64c3 GET /v1/drugs/9cb48086-6883-4358-bd31-b986f04d64c3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "240 mg / 80 mg",
"atc_label": "nivolumabi ja relatlimabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/22/1679/001",
"fimea_rel_id": "REL59029",
"authorised_at": "2022-09-15"
}See everything about nivolumab and relatlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.